SCHEMBL3586679

SCHEMBL3586679

CNCc1cc2cccnc2cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 1/20 0.53
NR4A2 P43354 1/20 0.45
CYP2A6 P11509 1/20 0.44
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
DOT1L Q8TEK3 2/20 0.41
ALDH1A1 P00352 5/20 0.41
PLK1 P53350 1/20 0.40
SLC6A2 P23975 3/20 0.40
SLC6A4 P31645 3/20 0.40
SLC6A3 Q01959 3/20 0.40
NPC1 O15118 2/20 0.40
POLB P06746 2/20 0.40
RAB9A P51151 2/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
NOS1 P29475 2/20 0.38
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
CASP1 P29466 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3584680 0.79 CASP6 (0.57) CASP6NR4A2PDGFRBPDGFRADOT1L
SCHEMBL27835033 0.79 CASP6 (0.57) CASP6NR4A2PDGFRBPDGFRADOT1L
SCHEMBL3407645 0.79 CASP6 (0.57) CASP6NR4A2PDGFRBPDGFRADOT1L
SCHEMBL24368437 0.78 CASP6 (0.53) CASP6NR4A2PDGFRBPDGFRADOT1L
SCHEMBL1750620 0.75 CASP6 (0.71) CASP6NR4A2PDGFRBPDGFRADOT1L
SCHEMBL24368384 0.74 CASP6 (0.51) CASP6NR4A2DOT1LALDH1A1PLK1
SCHEMBL11102883 0.73 CASP6 (0.54) CASP6NR4A2PDGFRBPDGFRADOT1L
SCHEMBL3587114 0.73 CASP6 (0.62) CASP6NR4A2PDGFRBPDGFRADOT1L
SCHEMBL3005405 0.72 ALDH1A1 (0.53) CYP2A6ALDH1A1PLK1NPC1POLB
SCHEMBL2206223 0.72 ALDH1A1 (0.53) NR4A2CYP2A6ALDH1A1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP disclosed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E CASP6 2702/4885NR4A2 2236/4885CYP2A6 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.